Marjan Ghiti Moghadam
University of Twente
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Marjan Ghiti Moghadam.
Arthritis & Rheumatism | 2016
Marjan Ghiti Moghadam; Harald E. Vonkeman; Peter M. ten Klooster; Janneke Tekstra; Dirkjan van Schaardenburg; Mirian Starmans-Kool; Elisabeth Brouwer; Reinhard Bos; Willem F. Lems; Edgar M. Colin; Cornelia F Allaart; Inger L. Meek; Robert Landewé; Hein J. Bernelot Moens; Piet L. C. M. van Riel; Mart A F J van de Laar; Tim L. Jansen
Tumor necrosis factor inhibitor (TNFi) biologic agents are an effective treatment for rheumatoid arthritis (RA). It is unclear whether patients whose disease is in remission or who have stable low disease activity need to continue use of TNFi or can stop this treatment. This study was undertaken to assess whether patients with established RA who are in remission or have stable low disease activity can effectively and safely stop their TNFi therapy.
Arthritis & Rheumatism | 2016
Marjan Ghiti Moghadam; Harald E. Vonkeman; Peter M. ten Klooster; Janneke Tekstra; Dirkjan van Schaardenburg; Mirian Starmans-Kool; Elisabeth Brouwer; Reinhard Bos; Willem F. Lems; Edgar M. Colin; Cornelia F Allaart; Inger L. Meek; Robert Landewé; Hein J. Bernelot Moens; Piet L. C. M. van Riel; Mart A F J van de Laar; Tim L. Jansen
Tumor necrosis factor inhibitor (TNFi) biologic agents are an effective treatment for rheumatoid arthritis (RA). It is unclear whether patients whose disease is in remission or who have stable low disease activity need to continue use of TNFi or can stop this treatment. This study was undertaken to assess whether patients with established RA who are in remission or have stable low disease activity can effectively and safely stop their TNFi therapy.
Arthritis & Rheumatism | 2016
Marjan Ghiti Moghadam; Harald E. Vonkeman; Peter M. ten Klooster; Janneke Tekstra; Dirkjan van Schaardenburg; Mirian Starmans-Kool; Liesbeth Brouwer; Reinhard Bos; Willem F. Lems; Edgar M. Colin; Cornelia F Allaart; Inger L. Meek; Robert Landewé; Hein J. Bernelot Moens; Piet L. C. M. van Riel; Mart A F J van de Laar; Tim L. Jansen
Tumor necrosis factor inhibitor (TNFi) biologic agents are an effective treatment for rheumatoid arthritis (RA). It is unclear whether patients whose disease is in remission or who have stable low disease activity need to continue use of TNFi or can stop this treatment. This study was undertaken to assess whether patients with established RA who are in remission or have stable low disease activity can effectively and safely stop their TNFi therapy.
PLOS ONE | 2018
Marjan Ghiti Moghadam; F.B.G. Lamers-Karnebeek; Harald E. Vonkeman; Peter M. ten Klooster; Janneke Tekstra; Annemarie M. Schilder; H. Visser; Eric H. Sasso; David Chernoff; Willem F. Lems; Dirk Jan Van Schaardenburg; Robert Landewé; Hein J. Bernelot Moens; Timothy R. D. J. Radstake; Piet L. C. M. van Riel; Mart A F J van de Laar; Tim L. Jansen
Objective Successfully stopping or reducing treatment for patients with rheumatoid arthritis (RA) in low disease activity (LDA) may improve cost-effectiveness of care. We evaluated the multi-biomarker disease activity (MBDA) score as a predictor of disease relapse after discontinuation of TNF inhibitor (TNFi) treatment. Methods 439 RA patients who were randomized to stop TNFi treatment in the POET study were analyzed post-hoc. Three indicators of disease relapse were assessed over 12 months: 1) restarting TNFi treatment, 2) escalation of any DMARD therapy and 3) physician-reported flare. MBDA score was assessed at baseline. Associations between MBDA score and disease relapse were examined using univariate analysis and multivariate logistic regression. Results At baseline, 50.1%, 35.3% and 14.6% of patients had low (<30), moderate (30−44) or high (>44) MBDA scores. Within 12 months, 49.9% of patients had restarted TNFi medication, 59.0% had escalation of any DMARD and 57.2% had ≥1 physician-reported flare. MBDA score was associated with each indicator of relapse. At least one indicator of relapse was observed in 59.5%, 68.4% and 81.3% of patients with low, moderate or high MBDA scores, respectively (P = 0.004). Adjusted for baseline DAS28-ESR, disease duration, BMI and erosions, high MBDA scores were associated with increased risk for restarting TNFi treatment (OR = 1.85, 95% CI 1.00–3.40), DMARD escalation (OR = 1.99, 95% CI 1.01–3.94) and physician-reported flare (OR = 2.00, 95% 1.06–3.77). Conclusion For RA patients with stable LDA who stopped TNFi, a high baseline MBDA score was independently predictive of disease relapse within 12 months. The MBDA score may be useful for identifying patients at risk of relapse after TNFi discontinuation.
Arthritis Care and Research | 2018
Marjan Ghiti Moghadam; Peter M. ten Klooster; Harald E. Vonkeman; Eva L. Kneepkens Md; Ruth Klaasen Md; Jan N. Stolk Md; I. Tchetverikov; Simone A. Vreugdenhil; Jan Maarten van Woerkom; Y P M Goekoop-Ruiterman; Robert Landewé; Piet L. C. M. van Riel; Mart A F J van de Laar; Tim L. Jansen
To determine the impact of stopping tumor necrosis factor inhibitor (TNFi) treatment on patient‐reported outcomes (PROs) of physical and mental health status, health utility, pain, disability, and fatigue in patients with established rheumatoid arthritis (RA).
Arthritis & Rheumatism | 2018
An Tran-Duy; Marjan Ghiti Moghadam; Martijn A. H. Oude Voshaar; Harald E. Vonkeman; Annelies Boonen; Philip Clarke; Geoff McColl; Peter M. ten Klooster; T.R. Zijlstra; Willem F. Lems; N. Riyazi; En Griep; Johanna M. W. Hazes; Robert Landewé; Hein J. Bernelot Moens; Piet L. C. M. van Riel; Mart A F J van de Laar; T.L. Jansen
To evaluate, from a societal perspective, the incremental cost‐effectiveness of withdrawing tumor necrosis factor inhibitor (TNFi) treatment compared to continuation of these drugs within a 1‐year, randomized trial among rheumatoid arthritis patients with longstanding, stable disease activity or remission.
Arthritis & Rheumatism | 2018
An Tran-Duy; Marjan Ghiti Moghadam; Antonius H. Oude Voshaar; Harald E. Vonkeman; Annelies Boonen; Clarke Philip; Geoff McColl; Peter M. ten Klooster; T.R. Zijlstra; Willem F. Lems; N. Riyazi; En Griep; Mieke Hazes; Robert Landewé; Hein J. Bernelot Moens; P.L.C.M. van Riel; Mart A F J van de Laar; Tim L. Jansen
To evaluate, from a societal perspective, the incremental cost‐effectiveness of withdrawing tumor necrosis factor inhibitor (TNFi) treatment compared to continuation of these drugs within a 1‐year, randomized trial among rheumatoid arthritis patients with longstanding, stable disease activity or remission.
The Journal of Rheumatology | 2017
Martijn A. H. Oude Voshaar; Marjan Ghiti Moghadam; Harald E. Vonkeman; Peter M. ten Klooster; Dirkjan van Schaardenburg; Janneke Tekstra; H. Visser; Mart A F J van de Laar; Tim L. Jansen
Objective. To evaluate and compare the utility of commonly used outcome measures for assessing disease exacerbation or flare in patients with rheumatoid arthritis (RA). Methods. Data from the Dutch Potential Optimalisation of (Expediency) and Effectiveness of Tumor necrosis factor-α blockers (POET) study, in which 462 patients discontinued their tumor necrosis factor-α inhibitor, were used. The ability of different measures to discriminate between those with and without physician-reported flare or medication escalation at the 3-month visit (T2) was evaluated by calculating effect size (ES) statistics. Responsiveness to increased disease activity was compared between measures by standardizing change scores (SCS) from baseline to the 3-month visit. Finally, the incremental validity of individual outcome measures beyond the Simplified Disease Activity Score was evaluated using logistic regression analysis. Results. The SCS were greater for disease activity indices than for any of the individual measures. The 28-joint Disease Activity Score, Clinical Disease Activity Index, and Simplified Disease Activity Index performed similarly. Pain and physician’s (PGA) and patient’s global assessment (PtGA) of disease activity were the most responsive individual measures. Similar results were obtained for discriminative ability, with greatest ES for disease activity indices followed by pain, PGA, and PtGA. Pain was the only measure to demonstrate incremental validity beyond SDAI in predicting 3-month flare status. Conclusion. These results support the use of composite disease activity indices, patient-reported pain and disease activity, and physician-reported disease activity for measuring disease exacerbation or identifying flares of RA. Physical function, acute-phase response, and the auxiliary measures fatigue, participation, and emotional well-being performed poorly.
Arthritis & Rheumatism | 2016
Marjan Ghiti Moghadam; Harald E. Vonkeman; Peter M. ten Klooster; Janneke Tekstra; Dirkjan van Schaardenburg; Mirian Starmans-Kool; Elisabeth Brouwer; Reinhard Bos; Willem F. Lems; Edgar M. Colin; Cornelia F Allaart; Inger L. Meek; Robert Landewé; Hein J. Bernelot Moens; Piet L. C. M. van Riel; Mart A F J van de Laar; Tim L. Jansen
Tumor necrosis factor inhibitor (TNFi) biologic agents are an effective treatment for rheumatoid arthritis (RA). It is unclear whether patients whose disease is in remission or who have stable low disease activity need to continue use of TNFi or can stop this treatment. This study was undertaken to assess whether patients with established RA who are in remission or have stable low disease activity can effectively and safely stop their TNFi therapy.
Arthritis & Rheumatism | 2016
Marjan Ghiti Moghadam; Harald E. Vonkeman; Peter M. ten Klooster; Janneke Tekstra; Dirkjan van Schaardenburg; Mirian Starmans-Kool; Elisabeth Brouwer; Reinhard Bos; Willem F. Lems; Edgar M. Colin; Cornelia F Allaart; Inger L. Meek; Robert Landewé; Hein J. Bernelot Moens; Piet L. C. M. van Riel; Mart A F J van de Laar; Tim L. Jansen
Tumor necrosis factor inhibitor (TNFi) biologic agents are an effective treatment for rheumatoid arthritis (RA). It is unclear whether patients whose disease is in remission or who have stable low disease activity need to continue use of TNFi or can stop this treatment. This study was undertaken to assess whether patients with established RA who are in remission or have stable low disease activity can effectively and safely stop their TNFi therapy.